ARX102 / Sino Biopharm, J&J - LARVOL DELTA

Johnson & Johnson Completes Acquisition of Ambrx (Businesswire) - "Johnson & Johnson...announced today it has successfully completed the acquisition of Ambrx Biopharma, Inc...in an all-cash merger transaction for a total equity value of approximately $2.0 billion, or $1.9 billion net of estimated cash acquired, as announced on January 8, 2024...'We’re pleased to welcome Ambrx’s talented scientific team and proprietary ADC platform to Johnson & Johnson. We look forward to continuing the development of ARX517, which represents a potential first- and best-in-class PSMA-targeting ADC for the treatment of metastatic castration-resistant prostate cancer.'....The acquisition presents a distinct opportunity for Johnson & Johnson to design, develop and commercialize targeted oncology therapeutics."

M&A • Breast Cancer • Castration-Resistant Prostate Cancer • Gastric Cancer • Gastrointestinal Cancer • Genito-urinary Cancer • Hematological Malignancies • HER2 Breast Cancer • Metastatic Castration-Resistant Prostate Cancer • Oncology • Prostate Cancer • Solid Tumor

Ambrx Biopharma Inc. Announces Strategic Reprioritization and Provides Corporate Update (GlobeNewswire) - "Anticipated Near Term Pipeline Milestones: 2H 2023: Ambrx sponsored globally (U.S.) Interim Phase 1a safety data for ARX517, leading to a recommended dose that would allow Ambrx to initiate a Phase 1b/2 trial; 2H 2023: Initiation of Ambrx sponsored globally (U.S.) Phase 1a trial for ARX305 (subject to results from NovoCodex sponsored trial); 1H 2024: IND submission for ARX102 (subject to results from Sino Biopharm sponsored trial)."

IND • New P1 trial • New P1/2 trial • P1 data • Oncology • Solid Tumor

Ambrx Biopharma Inc. Announces Strategic Reprioritization and Provides Corporate Update (GlobeNewswire) - "Ambrx will prioritize the progression of ARX517 through the clinic as the company’s new lead asset. The company believes ARX517 has the potential to be the first ADC therapy that specifically targets Prostate Specific Membrane Antigen (PSMA) to treat prostate cancer....Due to changes in the HER2 competitive landscape, Ambrx will no longer directly pursue our anti-HER2 antibody-drug conjugate (ADC) asset ARX788 as its lead clinical asset. As such, the company will pause development of Ambrx-sponsored clinical trials involving ARX788. Instead, Ambrx will continue to work collaboratively with NovoCodex and seek a development partner(s) ex-China to progress ARX788; Ambrx highly values its global partners and plans to continue working collaboratively with NovoCodex (ARX788, ARX305), Sino Biopharm (ARX102) and BeiGene (research collaboration); Additional pipeline programs, ARX305 (anti-CD70 ADC) and ARX102 (smart PEG-IL2), will continue in development."

Pipeline update • Breast Cancer • Genito-urinary Cancer • Oncology • Prostate Cancer • Solid Tumor